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Recently, leucine-rich repeat transmembrane pro-
teins (LRRTMs) were found to be synaptic cell-adhe-
sion molecules that, when expressed in nonneuronal
cells, induce presynaptic differentiation in contacting
axons. We now demonstrate that LRRTM2 induces
only excitatory synapses, and that it also acts to
induce synapses in transfected neurons similarly
to neuroligin-1. Using affinity chromatography, we
identified a- and b-neurexins as LRRTM2 ligands,
again rendering LRRTM2 similar to neuroligin-1.
However, whereas neuroligins bind neurexins con-
taining or lacking an insert in splice site #4, LRRTM2
only binds neurexins lacking an insert in splice
site #4. Binding of neurexins to LRRTM2 can produce
cell-adhesion junctions, consistent with a trans-
interaction regulated by neurexin alternative splicing,
and recombinant neurexin-1b blocks LRRTM2’s
ability to promote presynaptic differentiation. Thus,
our data suggest that two unrelated postsynaptic
cell-adhesion molecules, LRRTMs and neuroligins,
unexpectedly bind to neurexins as the same presyn-
aptic receptor, but that their binding is subject to
distinct regulatory mechanisms.INTRODUCTION
Synapse assembly, maturation, specification, and maintenance
are likely driven by a multitude of trans-synaptic cell-adhesion
molecules. Multiple synaptic cell-adhesion molecules may
contribute to these processes, including, but not limited to, neu-
rexins and neuroligins (Ushkaryov et al., 1992; Ichtchenko et al.,
1995), ephrins and Eph receptors (Torres et al., 1998), SynCAMs
(Biederer et al., 2002), and netrin G-ligands (NGLs) (Kim et al.,
2006). A key technical advance in studying synaptic cell-adhe-
sion molecules was the discovery that expression of such
proteins in nonneuronal cells can potently enhance the formation
of synapses onto these cells (i.e., induce presynaptic differenti-
ation of axons), when these cells are cocultured with neurons
(Scheiffele et al., 2000; Biederer et al., 2002; Graf et al., 2004;Kim et al., 2006). In this assay, referred to as the artificial
synapse-formation assay, SynCAMs, neuroligins/neurexins, and
NGLs are active (see references cited above). Most recently,
a family of neuronal leucine-rich repeat proteins called LRRTMs
was also identified as a group of postsynaptic proteins that are
active in this assay (Linhoff et al., 2009; Brose, 2009).
LRRTMs comprise a family of four homologous leucine-rich
repeat proteins that are selectively expressed in neurons with
a differential distribution in brain (Lauren et al., 2003). LRRTM1
is a maternally suppressed gene that is associated paternally
with handedness and schizophrenia (Francks et al., 2007;
Ludwig et al., 2009). All LRRTMs induce presynaptic differentia-
tion in artificial synapse-formation assays, and LRRTM2 is
localized to excitatory synapses (Linhoff et al., 2009). Moreover,
deletion of LRRTM1 in mice causes an increase in the immuno-
reactivity for the vesicular glutamate transporter VGLUT1 (Linh-
off et al., 2009), a morphological change similar to that observed
in neuroligin-3 R451C knockin mice (Tabuchi et al., 2007).
Together, these data indicate that LRRTMsmay be postsynaptic
cell-adhesion molecules that are similar to neuroligins. How-
ever, these data raise important new questions; for example,
do LRRTMs also alter synapse numbers in neurons, and more
significantly, with which presynaptic molecules do LRRTMs
interact?
Here we examined the role of LRRTMs in neurons, focusing on
LRRTM2 because of its well-documented localization to
synapses (Linhoff et al., 2009). We demonstrate that LRRTM2
selectively induces excitatory synapse formation in the artificial
synapse-formation assay, and increases excitatory synapse
density in transfected neurons. Moreover, we identify neurexins
as the presynaptic receptors for LRRTM2, and demonstrate that
neurexin binding to LRRTM2 is tightly regulated by alternative
splicing of neurexins at splice site #4 (SS#4). Our data expand
the trans-synaptic interaction network mediating synaptic cell
adhesion, and suggest that neurexins generally nucleate trans-
synaptic signaling.
RESULTS
LRRTM2 Induces Excitatory Presynaptic Specializations
in the Artificial Synapse-Formation Assay
We transfected COS-7 cells with plasmids encoding only
mVenus (control), or mVenus-fusion proteins of LRRTM2 or neu-
roligin-1, and cocultured the transfected COS-7 cells withNeuron 64, 791–798, December 24, 2009 ª2009 Elsevier Inc. 791
Figure 1. LRRTM2 Expression in COS-7 Cells and in Cultured Hippo-
campal Neurons Increases Excitatory Synapse Density
(A) LRRTM2 selectively promotes formation of excitatory synapses in the arti-
ficial synapse-formation assay. Hippocampal neurons were cocultured for 2
days with COS-7 cells expressing mVenus alone (control), an LRRTM2-mVe-
nus-fusion protein (LRRTM2), or an mVenus-fusion protein of neuroligin-1
lacking inserts in splice sites A and B (NL1DAB). Panels show representative
immunofluorescence images of the cocultures stained with antibodies to
mVenus (green: GFP) and to various presynaptic and postsynaptic markers
(red: VGLUT1, vesicular glutamate transporter 1; VGAT, vesicular GABA
transporter). Coincident green and red signals are shown in yellow (scale
bar = 25 mm; applies to all images). (B) Quantitation of the artificial synapse
formation activity of LRRTM2 and neuroligin-1. Experiments as described in
(A) were quantified by measuring the ratio of the synaptic marker staining to
mVenus fluorescence (for absolute red and green fluorescence values, see
Figure S1). (C) Representative images of cultured hippocampal neurons
that were transfected at DIV10 with mVenus alone (control), an LRRTM2
mVenus-fusion protein (LRRTM2), or an mVenus-fusion protein of neuroligin-1
lacking inserts in splice sites A and B (NL1DAB). Cultures were analyzed at
DIV14 by double immunofluorescence with antibodies to mVenus and the
synaptic markers described above for (A) (scale bar = 5 mm, applies to all
images). (D and E) Effect of LRRTM2 and neuroligin-1 on synapse density
(D) and synaptic signal intensity (E), which were quantified with the indicated
markers in neurons transfected with mVenus alone (control), the LRRTM2
mVenus-fusion protein (LRRTM2), or the neuroligin-1 mVenus-fusion protein
(NL1DAB). All data shown are means ± SEMs (n = 3 independent culture exper-
iments). Statistical significance was assessed by comparing the LRRTM2
and neuroligin-1 effects with the control using Student’s t test (*p < 0.05;
**p < 0.01).
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samples were fixed, immunolabeled for mVenus and synaptic
markers, and analyzed by quantitative fluorescence microscopy
(Figures 1A and 1B).
Immunostaining for synapsin confirmed that LRRTM2, similarly
to neuroligin-1, induced formationof stable presynaptic terminals
onto transfected COS-7 cells (Linhoff et al., 2009). Analysis with
antibodies to the vesicular glutamate and GABA transporters
(VGLUT1 and VGAT, respectively) demonstrated that LRRTM2
only induced formation of excitatory, VGLUT1-containing syn-
apses on transfected COS-7 cells, whereas neuroligin-1 induced
formation of both excitatory and inhibitory synapses (Figures 1A,
1B, and S1A [the latter available online]). Neither LRRTM2 nor
neuroligin-1 produced formation of synaptic specializations
containing the postsynaptic marker PSD-95.
Neuronal Overexpression of LRRTM2 Increases
Excitatory Synapse Numbers
We next examined whether the effect of LRRTM2 can also affect
synapse density in neurons. We transfected cultured hippo-
campal neurons at 10 days in vitro (DIV10) with plasmids encod-
ing onlymVenus (control), or mVenus-fusion proteins of LRRTM2
or neuroligin-1, and fixed and immunostained the neurons at
DIV14. Using image analysis, we quantified the density and
signal intensity of immunoreactive synaptic puncta identified
with antibodies for various presynaptic and postsynaptic
markers and for mVenus (Figures 1C–1E). LRRTM2 potently
increased the density of excitatory, but not inhibitory, synapses
on transfected neurons, as measured with both presynaptic and
postsynaptic marker proteins. In this assay, LRRTM2 thus again
acted similarly to neuroligin-1, but was more effective (Figures
Figure 2. Affinity Purification of Neurexins
on Immobilized LRRTM2
(A) Coomassie-stained gel of recombinant Ig-
control (IgC) and Ig-LRRTM2-fusion proteins
used for affinity chromatography and pull-down
experiments. In the Ig-LRRTM2 lane, the lower
band (asterisk) is likely a breakdown product of
the full-length Ig-LRRTM2-fusion protein. (B) Iden-
tification of neurexins as LRRTM2-receptors.
Proteins solubilized with Triton X-100 from total
rat brain homogenate (Brain Homogenate) were
passed through a column containing immobilized
IgC or Ig-LRRTM2. After collection of the flow-
through (FT), the column was washed extensively
with homogenization buffer (Wash), and eluted
with 0.5 M NaCl (not shown) and 1.0 M NaCl
(Eluate). Fractions were analyzed by SDS-PAGE
and silver staining as shown, and eluted proteins
above 80 kDa were subjected to mass spectrom-
etry, with identification of 140 peptides as indi-
cated on the right. (C) Immunoblotting analysis of
solubilized rat brain membrane proteins (Input;
5% of total) subjected to pull-down experiments
with IgC or Ig-LRRRTM2-fusion protein. Equiva-
lent amounts of bound proteins were analyzed
with the antibodies indicated below the panels
(GABARb3, b3 subunit of GABAA-receptors;
NGLs, netrin-G ligands; NMDAR1, NMDA receptor
subunit 1).
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presynaptic markers per punctum on the transfected neurons,
also similarly to neuroligin-1. However, unlike neuroligin-1,
LRRTM2 had no significant effect on the postsynaptic signal
(Figures 1C–1E).
Neurexins Are Candidate Presynaptic Ligands
for LRRTM2
To search for presynaptic ligands of postsynaptic LRRTM2, we
produced recombinant LRRTM2 composed of the entire extra-
cellular sequence of LRRTM2 fused to the Fc-domain of human
IG (Ig-LRRTM2), analogous to previously generated neurexin-
fusion proteins (Ushkaryov et al., 1994). As a control, we used
IgC that is composed of the first 18 residues of mature neu-
rexin-1a fused to the Fc-domain of human IG. Ig-fusion proteins
were produced in transfected HEK293T cells, and purified on
protein A-Sepharose (Figure 2A). We then performed affinity
chromatography experiments with solubilized rat brains on the
immobilized Ig-fusion proteins (Figure 2B).
Silver staining of SDS polyacrylamide gels loaded with the
input, wash, and eluate fractions from affinity chromatography
experiments suggested that multiple bands are purified on
immobilized LRRTM2. We performed mass spectrometry anal-
yses of all proteins larger than Ig-LRRTM2 in the silver-stained
gels. Of 140 identified peptides, 31 peptides were derived
from neurexins, with all three a-neurexins represented, and 18
peptides were from synaptotagmin-1, which binds to neurexins
(Figure 2B; Hata et al., 1993). Besides neurexins, no other cell-
surface proteins were identified in the LRRTM2 affinity-purified
fractions, suggesting that neurexins are the most abundant
and/or the most tightly bound extracellular interaction partners
of LRRTM2.To confirm that LRRTM2 indeed pulls down neurexins present
in detergent-solubilized membrane fractions, we used immuno-
blotting to analyze which proteins were captured by immobilized
LRRTM2 (Figure 2C). We observed a high degree of enrichment
of a- and b-neurexins in the LRRTM2-bound fraction, but not of
any other cell-surface protein tested, confirming the mass spec-
troscopy results.
LRRTM2 Directly Binds a- and b-Neurexins in Cell
Surface Labeling Assays
To test whether neurexins can directly bind to LRRTM2 on the
surface of a cell, we bound various recombinant Ig-fusion
proteins of neurexins to HEK293T cells that express full-length
LRRTM2-mVenus. We fixed the cells without detergent, and
measured surface-bound Ig-fusion proteins by indirect immuno-
fluorescence (Figure 3A). As a negative control, we used IgC, and
as a positive control, we employed cells transfected with two
different neuroligin-1 splice variants. We found that both neu-
rexin-1a and -1b avidly bound to LRRTM2 in this assay, but
only when the neurexins lacked an insert in SS#4. In contrast
(but as reported previously; see Boucard et al., 2005), neu-
rexin-1a containing or lacking an insert in SS#4 did not bind to
neuroligin-1 containing an insert in splice sites A and B, but did
bind to neuroligin-1 lacking an insert in splice sites A and B.
Neurexin-1b, similarly to neurexin-1a, also bound to LRRTM2
dependent on SS#4 of neurexin-1b, whereas its binding to neu-
roligin-1 was independent of neurexin-1b alternative splicing
(Figure 3A). Thus, binding of neurexin-1a and -1b to LRRTM2
and to neuroligin-1 is differentially controlled by alternative
splicing at SS#4 of neurexins, suggesting that neurexin binding
to LRRTM2 and neuroligins operates via distinct but related
mechanisms. This conclusion is reinforced by the finding thatNeuron 64, 791–798, December 24, 2009 ª2009 Elsevier Inc. 793
Figure 3. Analysis of LRRTM2/Neurexin Interaction with Cell-
Surface Binding and Cell-Adhesion Assays
(A) Surface-binding assays. HEK293T cells expressing mVenus-fusion
proteins of LRRTM2, or of two different splice variants of neuroligin-1
(NL1AB, which contains an insert in splice sites A and B, and NL1DAB, which
lacks in insert in these sites), were incubated with control Ig-fusion protein
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dependent (Figure 3A).
LRRTM2 Binding to Neurexins Mediates Cell Adhesion
To investigate whether binding of LRRTM2 to neurexins is
a trans-interaction, i.e., capable of promoting intercellular cell
adhesion (as expected for an interaction between a postsynaptic
cell-adhesion molecule and presynaptic neurexins), we exam-
ined the ability of surface-expressed LRRTM2 to mediate cell
adhesion with cells expressing neurexins. We transfected
HEK293T cells with (1) mVenus or tdTomato alone; (2) mVenus-
fusion proteins of LRRTM2; (3) mVenus-fusion protein of neuro-
ligin-1, (4) mCherry-fusion proteins of various neurexins; and (5)
tdTomato cotransfected with untagged LRRTM2. One day after
transfection, cells were dissociated, and mVenus-expressing
and tdTomato- or mCherry-expressing cells were mixed. Cells
were imaged immediately after mixing and after a 60min incuba-
tion at room temperature with mild agitation, and free cells were
counted at each time point to quantify cell adhesion (Figures 3B
and 3C).
Because at least in some instances, leucine-rich repeat
proteins mediate homophilic cell adhesion (e.g., see the role of
connectin in Drosophila synapse formation; Nose et al., 1992),
we first examined whether LRRTM2 mediates homophilic
cell adhesion by mixing red (tdTomato) and green (mVenus)
LRRTM2-expressing cells. However, we observed no cell
adhesion (Figure S3A). We next examined whether LRRTM2
binding to neurexins can mediate cell adhesion. Indeed, cells
expressing LRRTM2 formed large aggregates with cells ex-
pressing neurexin-1a or -1b, provided that the neurexins lacked
an insert in SS#4 (Nrx1aSS4 and Nrx1bSS4, but not Nrx1aSS4+
or Nrx1bSS4+; Figures 3B and 3C). All three b-neurexins bound
with the same splice-site dependence (Figures S3B and S3C).
This splice-site dependence was different from that observed
with neuroligin-1, where cells expressing neuroligin-1 lacking(IgC) or various neurexin Ig-fusion proteins (IgNrx1aSS4, IgNrx1aSS4+,
IgNrx1bSS4, and IgNrx1bSS4+ = Ig-fusion proteins of neurexin-1a and -1b,
respectively, lacking or containing an insert in splice site #4, respectively).
Cells were analyzed by immunofluorescence imaging for the Ig-fusion proteins
(red) andmVenus (green). All binding reactions were carried out in 2mMCaCl2,
except for the reaction marked by ‘‘EGTA,’’ which was performed in 10 mM
EGTA (scale bar = 4 mm, applies to all images). For further controls, see
Figure S2. (B and C) Representative images (B) and quantitation (C) of cell-
adhesion assays. HEK293T cells expressing mVenus (either alone [control]
or as an LRRTM2- or NL1DAB-fusion protein) were mixed with HEK293T cells
expressing tdTomato (Control) or mCherry fused with various neurexins
(Nrx1aSS4, Nrx1aSS4+, Nrx1bSS4, and Nrx1bSS4+ = neurexin-1a and -1b,
respectively, lacking or containing an insert in splice site #4 as indicated;
Nrx2bSS4 = neurexin-2b lacking an insert in splice site #4; Nrx2bSS4 was also
examined with a point mutation [D137A] that blocks neuroligin binding [Reiss-
ner et al., 2008]). Cells were imaged, and free cell numbers were counted
immediately after respective cell populations had been mixed (T0), and again
after 60 min (T60; shown in representative images in B; scale bar = 100 mm,
applies to all images). For additional representative images, see Figure S3.
Cell aggregation in (C) is calculated by dividing T0 by T60 (data shown are
means ± SEMs; n = 3 independent experiments; gray and black bars show
quantitations for mVenus and tdTomato/mCherry-expressing cells, respec-
tively; for more quantitations and controls, see Figure S4).
Figure 4. Exclusive Binding of Neurexin-1b to Either LRRTM2 or
Neuroligin-1, and Estimation of the LRRTM2-Neurexin Interaction
Affinity
(A) Immunoblot analysis of pull-downs of LRRTM1–4 expressed as EGFP- or
mVenus-fusion proteins in HEK293T cells. Pull-downs were performed with
immobilized Ig-control (IgC) and Ig-neurexin-fusion proteins (IgNrx1bSS4,
lacking an insert in splice site #4), using neuroligin-1 (NL1DAB) as a positive
control, and netrin G-ligand 3 (NGL-3) as a negative control (Input = 5% of
total). Numbers on the left in this and subsequent panels indicate sizes of
molecular weight markers. (B) Same as (A), except that pull-downs were per-
formed with IgC and Ig-LRRTM2-fusion proteins (Ig-LRRTM2), and that we
analyzed binding of neurexin-1a and -1b lacking or containing an insert in
splice site #4 (Nrx1aSS4, Nrx1aSS4+, Nrx1bSS4, and Nrx1bSS4+, respectively;
all expressed as mCherry-fusion proteins), using neuroligin-1 (NL1DAB,
expressed as an mVenus-fusion protein) as a positive control. (C) Neurexin-
1b bound to neuroligin-1 cannot simultaneously bind to LRRTM2. Purified
Ig-LRRTM2, HA-tagged neurexin-1b (HA-Nrx1bSS4), and FLAG-tagged neu-
roligin-1 (FLAG-NL1DAB; 3 mg of each protein) were mixed and immunoprecip-
itated with FLAG antibodies. Input (5% of total) and bound proteins were
analyzed by immunoblotting as indicated. Asterisks (*) indicate IgG heavy or
light chains. (D) Neurexin-1b bound to LRRTM2 cannot simultaneously bind
to neuroligin-1. Purified Ig-LRRTM2, HA-Nrx1bSS4, and FLAG-NL1DAB (3 mg
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aggregates with all neurexins tested, consistent with the binding
data shown in Figure 3A.
However, similarly to neuroligin-1, LRRTM2-mediated cell
adhesion to neurexin-containing cells was strictly dependent
on Ca2+ binding to neurexins. Binding was abolished by EGTA,
and was blocked by a single amino-acid substitution in neu-
rexin-2b that abolishes Ca2+ binding to the neurexin LNS
domain, and also abolishes neuroligin-1-mediated cell adhesion
(Figures 3B, 3C, S3B, and S4). No cell adhesion in negative
controls was observed (Figures 3B and S4). Taken together,
these data demonstrate that LRRTM2 forms an intercellular
junction via a trans-interaction with a- and b-neurexins in
a manner that resembles that of neuroligin-1, but differs from
neuroligin-1 in its distinct regulation of the neurexins by alterna-
tive splicing.LRRTM2 and Neuroligin-1 Cannot Bind Simultaneously
to Neurexin-1b
To corroborate the surface-binding and cell-adhesion assays
with an independent approach, and to additionally test whether
neurexins also bind to other LRRTM isoforms, we performed
pull-down experiments using the immobilized Ig-fusion protein
of neurexin-1b lacking an insert in SS#4 (IgNrx1bSS4; Figure 4A).
We found that immobilized Ig-neurexin-1b effectively captured
all LRRTM isoforms (LRRTM1–4) and neuroligin-1 expressed
in HEK293T cells. However, Ig-neurexin-1b did not bind to
NGL-3, and IgC used as a negative control was unable to bind
to either LRRTMs or neuroligin-1.
We next reversed the assay, and employed the Ig-fusion
protein of LRRTM2 described above (see Figure 2) to pull
down neurexins expressed as mCherry-fusion proteins in
HEK293T cells. Strikingly, LRRTM2 pulled down only neurexins
lacking an insert in SS#4, and exhibited no activity toward neuro-
ligin-1, confirming the binding specificity observed in the cell-
surface binding and cell-adhesion assays (Figure 4B).
Neurexin binding by both neuroligin-1 and LRRTM2 depends
on Ca2+ binding to neurexins, and both binding reactions are
regulated, although differentially, by SS#4 of neurexins. These
observations indicate that despite their lack of homology,
LRRTM2 and neuroligin-1 may bind to overlapping sites on the
neurexin LNS domain. To test this hypothesis, we investigated
whether LRRTM2 and neuroligin-1 simultaneously bind to neu-
rexins. We produced recombinant Ig-LRRTM2, FLAG-tagged
neuroligin-1 lacking an insert in splice sites A and B (FLAG-
NL1DAB), and HA-tagged neurexin-1b lacking an insert in SS#4of each protein) were mixed and immunoprecipitated with protein A. Input
(5% of total) and bound proteins were analyzed by immunoblotting as indi-
cated. Asterisks (*) indicate IgG heavy and light chains. (E) Saturation binding
of Ig-neurexin-fusion protein (Nrx1bSS4) to LRRTM2 expressed in HEK293T
cells. Different concentrations of Nrx1bSS4 were incubated with HEK293T
cells transfected with mVenus-fusion protein of LRRTM2 or GW1 vector alone
(control), and the amount of bound Nrx1bSS4 was measured using an HRP-
labeled secondary antibody. The control signal observed in GW1 vector-trans-
fected HEK293T cells was subtracted to calculate net binding signals. The
inset shows a Scatchard plot analyzed by linear regression of the data, with
the calculated Kd as determined by three independent experiments.
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Figure 5. Soluble Ig-Neurexin Impairs Synaptogenic
Activity of LRRTM2: Model of LRRTM2 Action
(A and B) Representative images (A) and quantitation (B) of artifi-
cial synapse-formation assays to measure the effect of Ig-neu-
rexin-fusion protein lacking (Nrx1bSS4) or containing (Nrx1bSS4+)
an insert in splice site #4 on the synaptogenic activities of LRRTM2
and neuroligin-1. Cultured hippocampal neurons (DIV7) were
cocultured for 12 hr with COS-7 cells expressing mVenus-fusion
proteins of LRRTM2 or neuroligin-1 lacking inserts in splice sites
A and B (NL1DAB). Cocultures were performed in the presence of
50 mg/ml of IgC (control), IgNrx1bSS4, or IgNrx1bSS4+. Panels in
(A) show representative immunofluorescence images of the cocul-
tures stained with antibodies to mVenus (green, GFP) and synap-
sin (red; coincident signals, yellow; scale bar = 25 mm, applies to all
images). In (B), the immunofluorescence intensities for synapsin
and for mVenus were measured over the same transfected
COS-7 cells (left and middle bar graphs), and the ratios of synap-
sin to mVenus fluorescence signal were determined (right bar
graph). Dashed lines correspond to the IgC-treated values as
the baseline. Data shown are means ± SEMs (n = 3 independent
experiments, *p < 0.05). (C) Model for the trans-synaptic interac-
tions of neurexins with neuroligins and LRRTM2. Both bind to neu-
rexins via the 6th LNS domain that is shared by a- and b-neurexins,
but exhibit distinct specificities: neuroligins bind to neurexins in
a manner that is modulated by alternative splicing at site #4
without being absolutely dependent on this splice site, whereas
LRRTM2 binds to neurexins only if splice site #4 lacks an insert.
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combinations, and tested whether pull-downs of neuroligin-1
or LRRTM2 would capture not only neurexin-1b, but also
LRRTM2 or neuroligin-1, respectively (Figures 4C and 4D).
Unequivocally, neurexin-1b, but not LRRTM2, was brought
down with neuroligin-1. Similarly, only neurexin-1b, but not neu-
roligin-1, was brought down with LRRTM2 (Figures 4C and 4D).
These data demonstrate that neuroligin-1 and LRRTM2 cannot
simultaneously bind to neurexin-1b.
Finally, we estimated the binding affinity for the interaction of
LRRTM2 and neurexin-1b. LRRTM2-mVenus-expressing and
control HEK293T cells were incubated with increasing amounts
of Ig-neurexin-1b-fusion protein lacking an insert in SS#4, and
proteins bound to the cell surface were measured with an
HRP-tagged secondary antibody. After subtraction of nonspe-
cific binding, we calculated a nanomolar Kd by Scatchard anal-
ysis (5.83 ± 1.47 nM; Figure 4E). This result indicates that796 Neuron 64, 791–798, December 24, 2009 ª2009 Elsevier Inc.LRRTM2 binds to neurexins with high affinity, although
it should be noted that the dimeric neurexin ligands
used in these experiments produce an increased
apparent binding affinity.
Soluble Neurexin-1b Impairs the Synaptogenic
Activity of LRRTM2
Since neurexins directly interact with LRRTM2 (Figures
2, 3, and 4), the question arises of whether this interac-
tion is essential for the synaptogenic activity of
LRRTM2 (Figure 1). As a first test of this question, we
examined whether Ig-neurexin-1b lacking or contain-
ing an insert in SS#4 (IgNrx1bSS4 and IgNrx1bSS4+)
can block the function of LRRTM2 in the artificialsynapse formation assay (Figures 5A and 5B). In these experi-
ments, we used IgC as a negative control and neuroligin-1 as
a positive control, and restricted the coculture time to 12 hr to
avoid cellular uptake and degradation of the Ig-fusion proteins
(Chubykin et al., 2005).
IgNrx1bSS4, but not IgNrx1bSS4+, specifically reduced the
synaptogenic activity of LRRTM2 (Figures 5A and 5B), suggest-
ing that neurexins are indeed presynaptic receptors for LRRTM2
in the artificial synapse formation assay, similar to neuroligin
(Ko et al., 2009). Interestingly, the synaptogenic activity of neuro-
ligin-1 was also specifically reduced by IgNrx1bSS4, but not by
IgNrx1bSS4+, although neuroligin-1 (NL1DAB) binds to both
neurexin isoforms in vitro (Figure 3), possibly because of the
differences in neuroligin-1 binding affinities of the two different
neurexin splice variants (Boucard et al., 2005), or because of
the dependence of the artificial synapse-formation assay on
a-neurexin binding by neuroligin-1 (Ko et al., 2009).
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Synaptic cell adhesion not only mediates the initial establish-
ment of synapses, but also directs synapse specification,
controls synapse maintenance, and regulates synapses during
long-term synaptic plasticity. Moreover, the recent discovery
of multiple synaptic cell-adhesion molecules as candidate genes
for cognitive diseases such as autism, schizophrenia, and addic-
tion hasmoved synaptic cell adhesion into the center of attention
(reviewed in Su¨dhof, 2008). In particular, neurexin-1 has been
repeatedly linked to autism and schizophrenia (Kim et al.,
2008; Kirov et al., 2009; Rujescu et al., 2009), LRRTM1 was
linked to schizophrenia (Francks et al., 2007; Ludwig et al.,
2009), and neurexin-3 has been associated with reward path-
ways and drug addiction (Bierut et al., 2007). Thus, the recent
findings that LRRTMs are candidate synaptic cell-adhesion
molecules that are potent effectors in the artificial synapse-
formation assay (Linhoff et al., 2009) were of great interest
because they suggested that LRRTMs may define a novel
trans-synaptic cell-adhesion pathway that may contribute to
cognitive diseases. However, these results also raised important
questions, namely whether the artificial synapse-formation
activity of LRRTMs truly reflects a role in synapses formed
between neurons, whether this role applies to all types or
specific subtypes of synapses, and whether LRRTMs act as
homophilic cell-adhesion molecules analogous to the leucine-
rich repeat protein connectin (Nose et al., 1992), or function by
binding to an as yet unidentified presynaptic ligand.
In the present study, we have provided initial answers to these
questions by focusing on LRRTM2, the most abundant LRRTM
isoform. We show that LRRTM2 increases the abundance of
excitatory, but not inhibitory, synapses, not only in the artificial
synapse-formation assay, but also in transfected neurons.More-
over, we demonstrate that LRRTM2 is not a homophilic cell-
adhesion molecule, but instead binds to presynaptic neurexins
in a tight interaction that is regulated by alternative splicing of
neurexins at SS#4. Thus, our data unexpectedly show that
neurexins act by binding to two different downstream ligands,
neuroligins and LRRTMs, in a mutually exclusive manner, and
that their binding to these ligands is differentially regulated. As
illustrated in themodel (Figure 5C), thesefindingsplaceneurexins
at the core of two separate trans-synaptic cell-adhesion path-
ways, and indicate that the involvement of LRRTM1 and neu-
rexin-1 in schizophrenia may delineate a common mechanism.
As synaptic cell-adhesion molecules, LRRTMs could be
involved in one or several steps during synapse formation,
from their initial establishment to their maturation and remodel-
ing. The assays used in the present study—the artificial
synapse-formation and neuronal transfection assays—do not
allow conclusions about the steps in which a protein functions.
For example, in the artificial synapse-formation assay, even
control nonneuronal cells form transient synapses with cocul-
tured neurons; thus, if a molecule stabilizes or validates
synapses, it could in this assay stabilize synapses that are
initially established by an independent mechanism. In vivo,
neuroligins appear to be more important for synapse specifica-
tion, function, and plasticity than for the initial establishment of
synapses (Varoqueaux et al., 2006; Chubykin et al., 2007), andneurexins have a demonstrated role in synapse specification
and function, but not synapse establishment (Missler et al.,
2003; Kattenstroth et al., 2004; Zhang et al., 2005). However,
these findings do not necessarily mean that LRRTMs do not
function in the establishment of initial synapses, and even
neurexins might do so, because no complete neurexin deletion
has yet been analyzed. Moreover, we do not know whether
LRRTMs also bind to other presynaptic ligands, which is a
distinct possibility because neuroligins also appear to interact
with other presynaptic ligands besides neurexins (Ko et al.,
2009). Again, these are issues that will have to be addressed in
future studies.
EXPERIMENTAL PROCEDURES
Artificial Synapse-Formation Assays
Artificial synapse-formation assays were performed with COS-7 cells and
cocultured hippocampal neurons as described (Ko et al., 2009), and were
analyzed after 48 hr.
Affinity Chromatography
Affinity chromatography experiments were performed with rat brain proteins
solubilized with 1% Triton X-100, using immobilized LRRTM2-Ig or IgC-fusion
proteins as a matrix (Sugita et al., 2001; Boucard et al., 2005). Proteins bound
to LRRTM2 affinity matrix were identified by mass spectrometry (Stanford
University Mass Spectrometry Facility), and identifications were confirmed
by immunoblotting (Figure 2).
Cell-Surface Binding Assays
Cell-surface binding assays were performed with HEK293T cells as described
(Boucard et al., 2005).
Cell Aggregation Assays
Cell aggregation assays were performed with HEK293T cells essentially as
described (Nguyen and Su¨dhof, 1997). HEK293T cells expressing red or green
fluorescent proteins were mixed 24 hr after transfection, and incubated at 4C
under gentle agitation. Cell and aggregate numbers were counted immediately
after mixing (N0), and after 60 min incubation (N60). Aggregation is calculated
as N0/N60.
Primary Neuronal Culture, Transfections, Immunocytochemistry,
Image Acquisition, and Analyses
Cultured hippocampal neurons were transfected with LRRTM2-mVenus,
NL1DAB-mVenus, or mVenus at DIV10, and immunostained at DIV14 by the
indicated antibodies as described (Ko et al., 2009). Images of randomly chosen
transfected neurons were acquired using a confocal microscope (LSM510,
Zeiss or TCS2, Leica) with constant image settings. Z-stacked images were
converted to maximal projection, and were analyzed using MetaMorph
Software with area size and density of spines and presynaptic terminals per
50 mm of dendrite.
Constructs, Antibodies, and Miscellaneous Procedures
All biochemical procedures were performed as described (Boucard et al.,
2005; Chubykin et al., 2007). Recombinant proteins were produced in trans-
fected HEK293T cells (Ushkaryov et al., 1994). Constructs were generated
as described in detail in the Supplemental Data. Antibodies and other reagents
were purchased commercially or described previously (Boucard et al., 2005;
Chubykin et al., 2007; for a detailed description, see Supplemental Data).
Statistics
All data are expressed asmeans ± SEMs; all experiments were performedwith
at least three independent cultures, and evaluated statistically by Student’s t
test (n = culture numbers). Detailed methods for all procedures are described
in the Supplemental Data, and all numerical data are listed in Table S1 available
online.Neuron 64, 791–798, December 24, 2009 ª2009 Elsevier Inc. 797
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Supplemental data for this article include four figures, one table, and Supple-
mental Experimental Procedures and can be found at http://www.cell.com/
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